NCT01471379View on ClinicalTrials.gov

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Milnacipran

50mg Milnacipran PO, BID, for 6 weeks.

DRUG

Milnacipran

Milnacipran, 100mg PO, BID, for six weeks

DRUG

Milnacipran

Milnacipran, 50mg PO BID for 12 weeks

DRUG

Placebo

Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.

Trial Locations (1)

27599

UNC Center for Functional GI and Motility Disorders, Chapel Hill

Sponsors

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Spencer Dorn, MD, MPH

OTHER